

02/16/2017

Federal Communications Commission 445 12th Street SW Washington, DC 20554

Subject:

**Limited Agency Agreement** 

**OrthoAccel Technologies** 

FCC ID: 2AKKO-3

To Whom It May Concern:

We, OrthoAccel Technologies, hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number 2AKKO-3 under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is 02/16/2017. The Limited Agency Agreement expires on 02/16/2018, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

Tulika Balagopal

Project Engineer